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ABSTRACT  34 
BACKGROUND: Severely delayed elimination of methotrexate (MTX) is difficult to predict in 35 
patients treated with high-dose MTX (HD-MTX), but may cause life-threatening toxicity. It has not 36 
been defined how an increase in plasma creatinine best can be used as a predictor for severely delayed 37 
MTX elimination thus a guide for therapeutic interventions to minimize renal toxicity. 38 
METHODS: Pharmacokinetic data was retrospectively collected on 218 Danish children with acute 39 
lymphoblastic leukemia treated with HD-MTX 5 or 8 g/m
2 
on the NOPHO2000 protocol. Moderately 40 
delayed MTX elimination was defined as 42-hour plasma MTX ≥4.0-9.9 µM, and severely delayed 41 
elimination was defined as 42-hour plasma MTX ≥10 µM.   42 
RESULTS: Median 42-hour plasma MTX was 0.61 µM (IQR: 0.4-1.06 µM). Of 1295 MTX 43 
infusions with 5 g/m
2
 (n=140 patients) or 8 g/m
2 
(n=78 patients) 5.1% were severely (1.5%) or 44 
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infusions with MTX 5 g/m² (7.4% vs 0.0 to 4.1% for subsequent MTX infusions) (p<0.02). A 25 µM 46 
increase or a 1.5 fold increase in plasma creatinine within 36 hours from start of the MTX infusion 47 
had a sensitivity of 92% (95%CI: 82%-97%) and specificity 85% (95%CI: 83-87%) for predicting 48 
42h MTX ≥4.0 µM.  49 
CONCLUSIONS: A 25 µM increase or a 1.5 fold in plasma creatinine within 36 hours after start of a 50 
HD-MTX infusion can predict delayed MTX elimination, thus allowing intensification of hydration 51 
and alkalization to avoid further renal toxicity and promote the elimination of MTX.  52 
 53 
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1 ǀ  INTRODUCTION 55 
Methotrexate (MTX) is an important chemotherapeutic drug used in the treatment of acute 56 
lymphoblastic leukemia (ALL).[1] High-dose MTX (HD-MTX) 1-8 g/m² is used to overcome cellular 57 
resistance and promote transport into pharmacological sanctuaries (e.g. testes and central nervous 58 
system (CNS)).[1-3] The MTX elimination vary significantly between HD-MTX courses, and 59 
extremely slow MTX elimination is seen in up to 5% of patients with ALL.[4,5] The variation in 60 
MTX elimination is difficult to predict and can only to some extend be explained by age, gender, 61 
treatment protocol, and germline DNA polymorphisms.[6-8]  62 
 63 
MTX is primarily eliminated by renal filtration and nephrotoxicity is seen in up to 20% of all HD-64 
MTX infusions.[9-12]  Nephrotoxicity reduces the MTX elimination and results in life threatening 65 
systemic MTX exposure.[4,11,13] Early detection of MTX induced nephrotoxicity is important 66 
because increased hydration and urine alkalisation can promote the renal elimination of MTX and 67 
prevent further damage to the kidneys.[10,11] An increase in plasma creatinine has in some protocols 68 
been used as a biomarker to detect MTX induced nephrotoxicity.[9,12]  69 
 70 
Folinic acid is used as a rescue drug to counteract MTX induced intracellular toxicity.[14] In case of 71 
severely delayed MTX elimination, the dose of folinic acid has to be increased in proportion to the 72 
MTX concentration but this could theoretically circumvent the antileukemic effects of MTX.[15-17] 73 
Severely delayed MTX elimination is defined as a plasma MTX concentration ≥10 µM at 42 hours 74 
after start of the HD-MTX infusion.[18] In this study we examine how an increase in plasma 75 
creatinine (1.5 fold or 25 µM) and end of infusion plasma MTX can be markers of severely and 76 
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 2  ǀ   MATERIALS AND METHODS  78 
From January 2002 until June 2008, a total of  218 children were diagnosed with B-cell precursor or 79 
T-lineage ALL in Denmark and treated with HD-MTX on the ALL 2000 protocol from the Nordic 80 
Society for Pediatric Hematology and Oncology (NOPHO) (Supplemental Fig. 1).  81 
 82 
2.1 Risk grouping 83 
Patients were classified based on ALL subtype, age, white blood cell count (WBC), response to 84 
induction therapy and a number of unfavorable features as described elsewhere.[2] Patients with 85 
unfavorable features such as a high white blood cell counts WBC at diagnosis, T-cell 86 
immunophenotype, hypodiploid karyotype or cytogenetic rearrangements, CNS-involvement and 87 
testicular leukemia were classified as high-risk patients and received intensive therapy that included 8 88 
g/m² HD-MTX. Patients without unfavorable features were treated with either standard intensive 89 
therapy (SI) or intermediate intensive therapy (II) that included infusions with 5 g/m² HD-MTX.[2,19]  90 
 91 
2.2  High-dose MTX infusions  92 
The complete NOPHO2000 protocol has been described in detail elsewhere.[2] In the consolidation 93 
phase, patients with standard or intermediate risk ALL received oral 6-mercaptopurine (6MP) 25 94 
mg/m
2
/day in combination with three courses of 5 g/m
2 
HD-MTX at three weeks intervals. Patients 95 
with high-risk ALL received two or four courses of 8 g/m
2 
HD-MTX in the consolidation phase 96 
without concomitant 6MP. During the first year of oral MTX/6MP maintenance treatment, patients 97 
with standard-risk and intermediate-risk ALL received further five courses of 5 g/m
2 
HD-MTX at 98 
eight weeks intervals. High-risk patients were not treated with HD-MTX in the maintenance phase. 99 
The starting maintenance dose of oral 6MP was 75 mg/m
2









/L. During the HD-MTX infusions the patients received one dose of intraspinal 101 
MTX (dose 8, 10 or 12 mg depending on age). Prehydration 150 ml/m²/h was started four hours 102 
before the HD-MTX infusion. After the prehydration 10% of the HD-MTX dose was infused over an 103 
hour, and the remaining 90% of the dose was given during the next 23 hours. The first dose of folinic 104 
acid 15 mg/m² was given at 42 hours after start of the 5 g/m² HD-MTX infusion (after 36 hours for 8 105 
g/m²) and was repeated every 6
th
 hour until the plasma MTX concentration was below 0.2 mol/L. 106 
The dose of folinic acid was increased in case of delayed MTX elimination (Supplemental table 2). 107 
During and after the MTX infusion the hydration volume was 3000 ml/m
2
/day. Plasma creatinine was 108 
measured at baseline, 23 hours and 36 hours after start of the HD-MTX infusion. The total hydration 109 
volume was elevated to 4500 ml/m²/day if plasma MTX was ≥ 3 µM at 36 hours or ≥ 1 µM at 42 110 
hours after start of the HD-MTX infusion; or if plasma creatinine increased ≥ 1.5 fold within the first 111 
42 hours after start of the HD-MTX infusion. Additional bicarbonate was given if urine pH was below 112 
7.0 anytime before, during and after the HD-MTX infusion. 113 
 114 
At 42 hours after start of the HD-MTX infusion, moderately delayed MTX elimination was defined as 115 
plasma MTX 4.0-9.99 µM, and severely delayed MTX elimination was defined as plasma MTX ≥10 116 
µM.[18] Acute kidney injury stage one is according to the NCI Common Terminology Criteria for 117 
Adverse Events (CTCAE) defined as an increase in plasma creatinine of 0.3 mg/dl (26.4 µM) or 50% 118 
from baseline.[20]  119 
 120 
 121 
2.3  Statistics 122 
Receiver operating characteristic curves (ROC) were used to study the association between delayed 123 
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curve indicates that the cut-off value has both a high sensitivity and specificity as a predictor. All 125 
statistics were calculated using the statistical program STATA14. The HD-MTX treatment courses 126 
were considered as unrelated events. Analysis of variance (ANOVA) or Chi-squared tests were used 127 
to compare differences in means between groups. McNemar’s test was used to evaluate the 128 
differences in sensitivity and specificity between the predictors for delayed MTX elimination.  129 
 130 
3  ǀ   RESULTS 131 
3.1  Risk of moderately and severely delayed MTX elimination 132 
A total of 140 patients (51% females) with a mean age of 4.9 years (range 1.4-17.0 years) were treated 133 
with 5 g/m² HD-MTX according to the NOPHO2000 protocol for standard and intermediate risk ALL 134 
(missing data are given in Supplemental Fig. 1a). The mean MTX clearance was 117.4 ml/min/m² but 135 
HD-MTX infusions with delayed MTX elimination at 42-hour had a significantly lower MTX 136 
clearance 66.9 ml/min/m² compared to the infusions that were not delayed 119.1 ml/min/m² 137 
(difference in mean 52; 95%CI 35-68 ml/min/m²; P<0.001). The median end of infusion plasma MTX 138 
was 69 µM (IQR: 51-87 µM) and the median 42-hour plasma MTX was 0.53 µM (IQR: 0.37-0.89 139 
µM) for 5 g/m² HD-MTX.  140 
 141 
Of the 1052 infusions with 5 g/m² HD-MTX, 2.5% (n=26) in 23 patients were moderately delayed 142 
with plasma MTX 4-9.99 µM at 42 hours after start of the HD-MTX infusion (Fig. 1a). Only three 143 
(13%) of these 23 patients had more than one HD-MTX course with moderately delayed MTX 144 
elimination. HD-MTX lower infusion number (P<0.02) (7.4% vs 0.0 to 4.1% for subsequent MTX 145 
infusions) and older age (≥ 10 years) (P<0.001) were significantly associated with a higher risk of 146 
having one or more courses with moderately delayed MTX elimination, but gender had no significant 147 








Severely delayed MTX elimination with plasma MTX ≥ 10 µM at 42 hours after start of the 5 g/m² 150 
HD-MTX infusion was seen in 0.76% (n=8) of the infusions. One of these seven patients had two 151 
courses with severely delayed MTX elimination. The median age of patients with severely delayed 152 
MTX elimination was 10.2 years (range 3.2-14.7 years), and 57% of them were females. 153 
 154 
A total of 78 patients (44% females) with a mean age of 5.0 years (range 1.7 - 15.0 years) were treated 155 
with 8 g/m² HD-MTX according to the NOPHO2000 protocol for high risk ALL. The mean MTX 156 
clearance was 107.7 ml/min/m² but HD-MTX infusions with delayed MTX elimination at 42-hour had 157 
a significantly lower MTX clearance 69.5 ml/min/m² compared to the infusions that were not delayed 158 
113.3 ml/min/m² (difference in mean 43.8, 95%CI 27-60 ml/min/m²; P<0.001). The median end of 159 
infusion plasma MTX was 114 µM (IQR: 93-146 µM) and the median 42-hour plasma MTX was 1.1 160 
µM (IQR: 0.69-1.5 µM) for infusions with 8 g/m² HD-MTX. 161 
 162 
Of the 243 infusions with 8 g/m² HD-MTX, 8.6% (n=21) were moderately delayed with plasma MTX 163 
4-9.99 µM at 42 hours after start of the HD-MTX infusion, and 4.9% (n=12) were severely delayed 164 
with plasma MTX ≥10 µM at 42 hours. Fifty seven percent of the 33 courses with moderately or 165 
severely delayed MTX elimination occurred in the first of the four HD-MTX courses given to patients 166 
with high risk ALL (Fig. 1b).  167 
 168 
Of the 67 HD-MTX courses (5 and 8 g/m²) with moderately and severely delayed MTX elimination, 169 
50 patients were re-challenged with a by protocol dose of HD-MTX. Only 8.0% (n=4) of these 170 
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(Table 1). Before the re-challenge with HD-MTX all patients had plasma creatinine within the normal 172 
range, but 28% (n=14) of the patients experienced a 1.5 fold increase in plasma creatinine within 36 173 
hours from the start of the infusion as a result of the re-challenge with HD-MTX.  174 
 175 
3.2  Plasma creatinine as predictor of delayed MTX elimination 176 
At 42-hour, 5% of all HD-MTX infusions had plasma MTX >4.0 µM. The area under the ROC was 177 
high for a 1.5 fold and a 25 µM (~0.3 mg/dl) increase in plasma creatinine at 36-hour, meaning that 178 
these cut-off points would have high sensitivity and specificity for predicting severely and moderately 179 
delayed MTX elimination plasma MTX >4.0 µM (Supplement Fig. 2a-b). 180 
 181 
Only 31% (n=13) of the HD-MTX infusions with moderately or severely delayed MTX elimination 182 
were identified by a 1.5 fold increase in plasma creatinine at 23 hours after start of the infusion. At the 183 
23-hour time-point, a 1.5 fold increase in plasma creatinine was seen in 5.1% (n=39) of all 5 g/m² 184 
HD-MTX infusions, corresponding to a positive predictive value of only 13%. For infusions with 8 185 
g/m² HD-MTX, the positive predictive value was 50% at the 23 hour time-point. Not all patients had 186 
the plasma creatinine measured at end of the HD-MTX infusion and this could potentially be a 187 
selection bias. However, there was no difference in age, gender, HD-MTX infusion number or 188 
baseline plasma creatinine when infusions with 23-hour and 36-hour plasma creatinine was compared 189 
to infusion where only the 36-hour plasma creatinine was measured.  190 
 191 
At 36 hours after start of the HD-MTX infusion, a 1.5 fold increase in plasma creatinine identified 192 
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point, the positive predictive value was 20% for 5 g/m² HD-MTX, and 42% for 8 g/m² HD-MTX 194 
infusions (Table 2).  195 
 196 
A 25 µM increase in plasma creatinine at 36 hours after start of the HD-MTX infusion identified 197 
79.0% (n=49) of the infusions with moderately delayed MTX elimination (Table 2). In 7.9% (n=91) 198 
of all HD-MTX infusions there was a 25 µM increase in plasma creatinine, and 54% of these courses 199 
were moderately delayed. Thus, at 36 hours after start of the HD-MTX infusion, a 25 µM increase in 200 
creatinine had higher specificity as a predictor of delayed MTX elimination compared to a 1.5 fold 201 
creatinine increase (P<0.001) but the sensitivity was equal for the two tests. All of the HD-MTX 202 
infusions with severely delayed MTX elimination were identified at 36 hours after start of the infusion 203 
because of either a 1.5 fold or 25 µM increase in plasma creatinine.   204 
 205 
Although a 25 µM increase in plasma creatinine had similar sensitivity as a 1.5 increase, the two tests 206 
identified slightly different groups of patients with delayed MTX elimination (Fig. 2). In the youngest 207 
age group, a 1.5 fold increase in plasma creatinine identified some of the patients with delayed MTX 208 
elimination who did not have a 25 µM increase. Patients with delayed MTX elimination who had a 209 
1.5 fold increase in plasma creatinine but not a 25 µM (n=8), were younger (median age 3.8 years) 210 
than the patients with delayed MTX elimination who had a 25 µM increase in plasma creatinine 211 
(median age 9.5 years) (n=49; p=0.03). A combination of a 25 µM and 1.5 fold increase in plasma 212 
creatinine had a sensitivity of 93.8 (95%CI: 79.2–99.2) and specificity 87.2 (95%CI: 84.9–89.3) in 213 
predicting delayed MTX elimination.  214 
 215 
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End of infusion plasma MTX was available in 1027 HD-MTX infusions; median 74 µM (IQR: 54-96 217 
µM). There was no linear association between end of infusion plasma MTX and 42-hour MTX 218 
(Supplement Fig. 3). When end of infusion plasma MTX was tested as a predictor for delayed MTX 219 
elimination it was not possible to find a cut-off value that had both high sensitivity and specificity. 220 
This was illustrated by the small area under the ROC curve for end of infusion plasma MTX as a 221 
predictor of delayed MTX elimination (Supplement Fig. 2c). Supplemental table 1 shows the 222 
sensitivity and specificity for end of infusion plasma MTX 70 µM and 100 µM as predictors of 223 
delayed MTX elimination. 224 
 225 
4  ǀ   DISCUSSION 226 
When the 42-hour plasma MTX is above 5 µM in infusions with HD-MTX, the dose of leucovorin 227 
has to be increased proportionately to prevent systemic toxicity and this can theoretically rescue some 228 
of the leukemia cells.[15-17] When the 42-hour plasma MTX is above 10 µM in infusions with HD-229 
MTX, it is recommended to start treatment with the enzyme glucarpidase, that cleaves MTX into non-230 
toxic metabolites.[13] In this analysis, “delayed HD-MTX elimination” was defined as 42-hour 231 
plasma MTX>4 µM, because this cut-off would include the 5% of HD-MTX infusions with the 232 
slowest MTX elimination and need for the largest doses of rescue leucovorin or even treatment with 233 
glucarpidase. 234 
 235 
We found that despite the use of vigorous hydration and urine alkalization, moderately or severely 236 
delayed MTX elimination occurred in 3.2 % of all infusions with 5 g/m² HD-MTX and 4.2 times as 237 
often in 8 g/m² HD-MTX infusions. An increased plasma creatinine in relation to the HD-MTX 238 
infusion has in other studies been associated with decreased MTX clearance in children with 239 
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serve as an indicator for the kidneys capability to eliminate MTX.[22] To translate this knowledge 241 
into clinical practice we explored if a 25 µM or 1.5 fold increase in plasma creatinine could be used as 242 
early markers for severely and moderately delayed MTX elimination.  243 
 244 
This study, which included both 5 and 8 g/m² HD-MTX infusions showed that, at end of the HD-245 
MTX infusion, a 1.5 fold increase in plasma creatinine could only identified 14% of the infusions 246 
with severely delayed MTX elimination. This suggests, that the MTX induced nephrotoxicity 247 
occurred late during the HD-MTX infusion and it reflects the fact that plasma creatinine does not 248 
increase until the glomerular filtration rate is decreased significantly.[22] Similar, the end of infusion 249 
MTX concentration could not be used as a predictor with sufficiently high sensitivity and specificity. 250 
Not all patients had the plasma creatinine measured at end of the HD-MTX infusion and this could 251 
potentially have led to a selection bias.  252 
 253 
At 36 hours after start of the HD-MTX infusion, almost all (93.8%) HD-MTX infusions with severely 254 
or moderately delayed MTX elimination were identified by an increase in plasma creatinine. The 255 
much higher sensitivity at 36 hours vs 23 hours after start of the HD-MTX infusion strongly suggests 256 
that a significant number of patients with delayed MTX elimination could have been identified earlier 257 
than 36 hours after start of the HD-MTX infusion. For patients predisposed to develop delayed MTX 258 
elimination (eg. due to older age, or genetic background) it could therefore be relevant to measure the 259 
plasma creatinine at 30 hours after start of the HD-MTX infusion to evaluate if this could identify 260 
delayed MTX elimination at an even earlier time point.  261 
 262 
A 25 µM and a 1.5 fold increase in plasma creatinine had similar sensitivity in predicting delayed 263 
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elimination. In the oldest age group of patients, an absolute increase in plasma creatinine identified 265 
some patients with delayed MTX elimination who did not have a 1.5 fold increase in plasma 266 
creatinine. This is most likely because the youngest patients with a small muscle mass have low 267 
plasma creatinine concentrations.  268 
 269 
The risk of having severely or moderately delayed MTX elimination was strikingly higher in the first 270 
HD-MTX infusion compared to the HD-MTX infusions given later in the consolidation and 271 
maintenance treatment phases. Others have similarly found, that the MTX clearance is lowest in the 272 
first HD-MTX infusion,[8] and it was recently shown that treatment with carboxypeptidase for 273 
patients with severely delayed MTX elimination was primarily needed in the first HD-MTX infusion 274 
given to patients with ALL.[23] The first HD-MTX infusion was given shortly after the induction 275 
therapy, suggesting that factors, such as tumor lysis, or nephrotoxicity during the induction phase 276 
could have reduced the kidneys ability to eliminate MTX in the first HD-MTX infusion. 277 
Nephrotoxicity and reduced MTX clearance can also be caused as a result of concomitant use of 278 
other drugs (e.g. proton pump inhibitors and antibiotics).[24] However, plasma creatinine can 279 
theoretically also be used as biomarker for nephrotoxicity in these situations. 280 
 281 
In conclusion, the risk of having severely delayed MTX elimination was highest in the first of eight 282 
infusions with HD-MTX and correlated to older age and MTX dose. It was not possible to find an end 283 
of infusion plasma MTX cut-off value, which had both high sensitivity and specificity as a predictor 284 
of delayed MTX elimination. An absolute increase (25 µM) in creatinine at 36 hours after start of the 285 
infusion had higher specificity compared to a relative increase (1.5 fold), thus could be used as a 286 
predictor for moderately and severely delayed MTX elimination and allowing increased hydration and 287 
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TABLE 1 42-hour plasma MTX in the re-challenge infusions. 386 
 387 
TABLE 2 Creatinine as predictor of delayed MTX elimination (42 hour MTX ≥4 µM). 388 
 389 
FIGURE 1 Distribution of 42-hour plasma MTX concentrations versus HD-MTX infusion number 390 
for (A) HD-MTX 5 g/m² and (B) HD-MTX 8 g/m². MTX, methotrexate; HD-MTX, high-dose 391 
methotrexate. Numbers above the columns denote the number of HD-MTX infusions with 42-hour 392 
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FIGURE 2 HD-MTX infusions with and without an increase in plasma creatinine at the 36-hour. 395 
Outer circle includes 932 infusions, white background: infusions with 42-hour plasma MTX<4 µM, 396 
and grey background: infusions with 42-hour plasma MTX>4 µM. Inner left circle includes infusions 397 
with >50% increase in plasma creatinine. Inner right circle includes infusions with >25 µM increase 398 
in plasma creatinine. Numbers in the circles denotes number of infusions. Cr, plasma creatinine; 399 
MTX, methotrexate; HD-MTX, high-dose methotrexate.  The table displays the risk of delayed MTX 400 
elimination with the different combinations of increase in plasma creatinine.  401 
 402 
 403 
TABLE 1 42 hour plasma MTX in the re-challenge infusions. 404 
 5 g/m² 8 g/m² 
 N=34 N=33 
42-hour MTX (µM)   
<1 17 11 
1-1.99 7 8 
2-2.99 1 1 
3-3.99 0 1 
≥ 4 2 2 
Not re-challenged  6 9 
Missing data 1 1 
*Renal toxicity 5 (18%) 7 (30%) 
MTX, methotrexate. *Renal toxicity defined as 1.5 or 



































Delay : Total 
36-hour 50% Cr increase 
5 g/m²  
8 g/m² 
 
87.5 (71.0 - 96.5) 
86.7 (69.3 - 96.2) 
 
87.2 (84.9 - 89.3) 
81.2 (74.9 - 86.4) 
 
19.6 (13.4 - 27.0) 
41.9 (29.5 - 55.2) 
 
6.8 (5.5 - 8.5) 








81.3 (63.6 - 92.8) 
76.7 (57.7 - 90.1) 
 
96.2 (94.8 - 97.4) 
95.8 (91.9 - 98.2) 
 
43.3 (30.6 - 56.8) 
74.2 (55.4 - 88.1) 
 
21.5 (14.9 - 31.1) 








51.7 (32.5 – 70.6) 
78.6 (59.0 – 91.7) 
 
91.7 (89.7 – 93.4) 
37.1 (30.1 – 44.5) 
 
16.5 (9.5 - 25.7) 
15.8 (10.2 – 23.0) 
 
6.2 (4.1 – 9.4) 




Hour, hours after start of the MTX infusion. Cr, creatinine. MTX, methotrexate. PPV, positive predictive value.  LR+, positive likelihood ratio, CI, 
confidence interval, N, number of MTX infusions. 
